论文部分内容阅读
1例48岁男性患者因肝癌复发皮下注射重组人干扰素α2b,初始剂量为100万U,3次/周,1个月后调整为200万U,3次/周。初始用药1个月后患者出现畏寒、乏力、腰部及双下肢肌肉酸痛,且症状持续加重。甲状腺功能检测:促甲状腺激素(TSH)0.085 mU/L,游离三碘甲状腺原氨酸(FT3)2.20 pmol/L,游离甲状腺素(FT4)3.52 pmol/L。甲状腺超声示双侧甲状腺缩小,双侧甲状腺实质弥漫性损伤。停用重组人干扰素α2b注射液,给予左甲状腺素钠25μg/d口服。1个月后复查甲状腺功能:TSH 0.053 mU/L,FT3 2.52 pmol/L,FT4 9.51 pmol/L。
A 48-year-old male patient underwent subcutaneous injections of recombinant human interferon alpha 2b with a recurrence of hepatocellular carcinoma at an initial dose of 1 million U, 3 times / week, and adjusted to 2 million U, 3 times / week after 1 month. One month after the initial medication, patients experienced chills, weakness, sore muscles in the lower back and lower extremities, and the symptoms continued to worsen. Thyroid function test: 0.085 mU / L of TSH, 2.20 pmol / L of free triiodothyronine (FT3) and 3.52 pmol / L of free thyroxine (FT4). Thyroid ultrasound showed bilateral thyroid shrinkage, diffuse bilateral thyroid diffuse injury. Recombinant human interferon α2b injection was discontinued and levothyroxine sodium 25 μg / d orally administered. Thyroid function was examined after 1 month: TSH 0.053 mU / L, FT3 2.52 pmol / L, FT4 9.51 pmol / L.